These drugs, meant to help regulate diabetes may instead cause horrifying side effects including cancer.
New York, NY (PRWEB) August 06, 2013
The F.D.A. recently announced it was reviewing a study involving Incretin Mimetic drugs. These drugs work to treat type 2 diabetes but have been linked to acute pancreatitis. Further, the study that is the subject of the FDA review purports to show that there is also an increased risk of pancreatic and thyroid cancers. The drug may cause an increase in tumors in the thyroid and pancreas which could become malignant (cancerous) . *1
With 25 million diabetics in the United States, Incretin Memetic drugs comprise a large segment of the diabetes drug market. These drugs include Januvia, Janumet, Byetta and Victoza. Januvia, for instance, brought in revenue over $4 Billion. Janumet, a combination of Januvia and another popular drug, (Metformin) had sales of $1.65 Billion.
With the changing safety profile of these drugs, new concerns about their efficacy and benefits have been raised. A number of lawsuits have been initiated against the products manufacturers. *2
Rudolph F.X. Migliore, P.C. is working with nationally recognized associated firms to litigate claims against these diabetes drugs manufacturers for allegedly causing pancreatic or thyroid cancer.
At the New York law office of Rudolph F. X. Migliore, more than 35 years of experience gives us the knowledge to tackle complicated product liability cases for our clients and help them obtain compensation for their injuries. To schedule a free case evaluation, visit http://www.migliorelaw.com or call us toll free at 1-888-980-RFXM (7396).
*1-Food and Drug Administration, March 14, 2013- http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm
*2Lawyers and Settlements, July 16, 2013- http://www.lawyersandsettlements.com/articles/januvia-side-effects/januvia-lawsuit-side-effects-cancer-3-18900.html?utm_expid=36075222.QRdCdW42SWGLZa0nRc6K3w.0#.UfV01r-Lpbw